Jefferies Healthcare Conference
|
|
- Ezra Grant
- 5 years ago
- Views:
Transcription
1 Jefferies Healthcare Conference Jean-Marc BOTHY - CSO June 8, IBA SA
2 Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers; the company s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology and any statements using the terms could, believe, outlook, or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company s actual results to differ materially from those anticipated. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise. 2
3 IBA at a glance A world leading innovator in cancer diagnostics and treatment Number one provider of proton therapy solutions Global leader in dosimetry and particle accelerators 1,500 employees worldwide and growing 329M Most advanced PT offering Single and multi room systems equipped with cutting edge technology *Proteus ONE and Proteus PLUS are brand names of Proteus 235 3
4 IBA a global leader in proton therapy Share of installed base - rooms Total accumulated: 250 rooms IBA market share is 56% in US, 54% in APAC ex. Japan and 56% in EUR & ROW Including commercial PT rooms at end
5 IBA Group 2016 key figures 5
6 Proton therapy market drivers today s capacity gap Source : IBA internal modeling based on Model Based Approach developed in The Netherlands ( 6
7 Proton therapy capacity gap Estimation of RT and PT rooms needed by Radiotherapy rooms needed by 2035 estimated by Lancet Oncology Proton therapy rooms needed by 2035 extrapolated worldwide from the Horizon Scanning : Proton Therapy in the Netherlands apy200917e_0.pdf 7
8 IBA strategy 8
9 Why proton therapy? (The dose deposition) The therapeutic index Tumor control probability (TCP) Normal tissue complication probability (NTCP) Define the maximal dose deliverable as a function of acceptable tolerance Courtesy of El Naqa et al 2006a Int. J. Radiat. Oncol. Biol. Phys Courtesy of Prof Lagendijk 11
10 Proton therapy vs conventional radiotherapy Highest dose is near the point of beam entry. Highest dose is at the depth of the tumor target. Tumor dose is less than the entry dose. Dose is also delivered beyond the tumor target. Zero or almost no dose beyond Minimal radiation exposure of healthy organs Potential to reduce the risk of secondary cancers Potential to improve the quality of life for patients during and after treatment Possibility of retreatment 12
11 Updated PT global market dynamics Number of patients treated with PT rose 21% between 2012 and 2015 to (cumulated) Number of patients treated with PT in 2015: This still represents less than 1% of the ~ cancer patients treated every year with radiotherapy Patients treated Total rooms sold Room in operations Source: MEDraysintell 2016, IBA model, PTCog 2016, and others 11
12 Increasing relevance of proton therapy 108 trials open and recruiting Publications statistics per year End December 2016 Number of publications up to end of 2016 Data from
13 Rate of sales increasing 55% vs previous years PT market number of rooms sold per year Wider acceptance of PT Competitive dynamics Lower entry barriers to PT Technology evolving More centres opening Average p.a. 13
14 IBA s unique proton therapy solutions 360 m² Proteus ONE Proton therapy made easy Proteus PLUS Excellence in proton therapy 1800 m² Compact single-room IMPT solution Proteus ONE and Proteus PLUS are the brand names of the Proteus 235 Tailor-made IMPT solution 16
15 Size matters ProteusONE Other 360 gantry one room system Footprint Volume
16 Rational for compact one room system Budget for one room system Up to 35% more affordable 3 months longer to instal 3 times larger building ProteusONE Other 360 gantry one room system Proton therapy system OIS/TPS Building development costs financial cost Start-up expenses System 3 times heavier 16
17 No compromises PROVEN PENCIL BEAM SCANNING For highly conformal IMPT INSTANT 3D & CONE- BEAM CT* For Image-Guided PT PATIENT AND STAFF FRIENDLY Open environment Protect, Enhance and Save Lives 17
18 Proton therapy centers equipped by IBA (end 2016) Systems 21 Systems Treating Patients & 17 Systems in Construction & 8 Systems in Installation Total: 46 Systems Rooms 67 Rooms Treating Patients & 24 Rooms in Construction & 20 Rooms in Installation Total: 111 Rooms 2016: 8 systems sold (5 Proteus One) in US, UK, China, India, UAE and Belgium 2017: 2 Proteus One sold (Spain and Egypt) and selection for another Proteus One in Belgium. Proteus ONE Proteus PLUS 18
19 Our strategy is to create a virtuous circle in PT Enhance market penetration Develop regionalization Leverage partnership Strengthen market leadership Invest in clinical affairs initiatives Focus on product roadmap Accelerate PT adoption PARTNERSHIPS Build clinical & cost advantage Increase clinical relevance Reduce cost of modality 19
20 Expansion strategy new factory Assembly, integration and test of accelerators for Proteus ONE CAPEX: EUR 16 million investment program over 2 years Digital factory Green and sustainable Lean total combined capacity of 20 to 30 accelerators per year (from 8 to 10 today) Opening in Q
21 Image-guided proton therapy courtesy of Roberts Proton Therapy Center CBCT Penn Medicine, USA CT-on-rails, Trento, Italy 21
22 Excellence in proton therapy: integration TPS/OIS: open vendor strategy (freedom to choose according to your need) Treatment planning Oncology information system Proton treatment delivery system Xio (Elekta) : 12 centers Eclipse (Varian) : 7 centers RayStation (Raysearch) : 17 centers Mosaiq (Elekta) : 20 centers Aria (Varian) : 3 centers RayCare (Raysearch): In development IBA Pinnacle*(Philips) : 4 sites 22 30
23 2017 Q1 update Group revenues of EUR 73,2 million, up 13,5% compared to first quarter 2016 Proton Therapy and Other accelerators backlog amounts to EUR 316 million Proton Therapy revenues continue to grow with 8 projects now under installation simultaneously Other Accelerators show a drop from last year. Last year was boosted by the installation of two large high energy cyclotrons Dosimetry returns to growth up 19% to EUR 14.5 million Q (EUR 000) Q (EUR 000) Variance (EUR 000) Variance % Proton therapy ,8% Other Accelerators ,6% Dosimetry ,2% Total Net Sales ,4% 23
24 Guidance IBA expects to achieve revenue growth between 15% to 20% in 2017 and double digit thereafter The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by % dividend pay-out ratio target maintained for 2017 This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. 24
25 Thank you Protect, Enhance and Save Lives 25
The Best in Proton Therapy + Today and Tomorrow + IBA. Corporate Presentation. February 2017
The Best in Proton Therapy + Today and Tomorrow + IBA Corporate Presentation February 2017 Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2013 Pick up in revenues over H1 2013 due to good order book conversion Company on track to be selected for eight new proton therapy (PT) rooms in 2013 REBIT margin for
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationPROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationJanuary 2018 Dow Wilson President and Chief Executive Officer
J.P. Morgan 2018 Healthcare Conference January 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing.
More informationProton Therapy Market Outlook - Global Analysis
Proton Therapy Market Outlook - Global Analysis Proton Therapy Market Outlook - Global Analysis BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen
More informationJP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY
JP MORGAN HEALTHCARE CONFERENCE - 2017 DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN
More informationElekta Synergy Digital accelerator for advanced IGRT
Elekta Synergy Digital accelerator for advanced IGRT Setting the standard for confident care The Field of Radiation Therapy is Constantly Changing Being able to take full advantage of the latest clinical
More informationFROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017
FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips
More informationTHE BEST IN PROTON THERAPY TODAY AND TOMORROW
THE BEST IN PROTON THERAPY TODAY AND TOMORROW The figures speak for themselves As the leading provider of Proton Therapy, IBA is committed to making this advanced treatment available to cancer patients
More informationElekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation
Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationGlobal Radiation Therapy Market Report
Global Radiation Therapy Market Report ----------------------------------------- 2013 Executive Summary Radiotherapy is used to kill cancerous cells and is commonly used either alone or in combination
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationINVESTOR MEETING ASTRO 2013
INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, 2013 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Except for historical information, this news
More informationImaging Systems. Gene Saragnese EVP and GM Imaging Systems
Imaging Systems Gene Saragnese EVP and GM Imaging Systems 1 Imaging Systems Strategy Drive Customer & Patient Experience Quality, reliability and service delivery Ease of use, speed, comfort, dose Deliver
More informationPROTON THERAPY. MEDraysintell WORLD MARKET REPORT & DIRECTORY EDITION
MEDraysintell PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2018 A report written by Paul-Emmanuel Goethals & Richard Zimmermann 2018 www.medraysintell.com Proton Therapy remains a niche market,
More informationElekta Infinity Digital accelerator for advanced treatments
Elekta Infinity Digital accelerator for advanced treatments Redefining treatment precision, speed and control Confidence to increase conformance and speed without compromising target coverage Set yourself
More informationElekta: Emerging markets
Gynecologic Cancer InterGroup Cervix Cancer Research Network Elekta: Emerging markets Cervix Cancer Education Symposium, January 2016, Bangkok, Thailand 144,000 deaths were related to cervical cancer in
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationElekta R&D Update 22 January 2015, Utrecht
1 Elekta R&D Update 22 January 2015, Utrecht Elekta R&D Update - 22 January 2015, Utrecht 11.00 R&D Update Niklas Savander President and CEO 11.15 Atlantic Positioning Dee Mathieson, SVP Oncology Business
More informationCYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.
CYCLOTRONS USED IN NUCLEAR MEDICINE WORLD MARKET REPORT & DIRECTORY MARKET DATA, COMPANIES PROFILES TOC and Summary EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/5
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationClosing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011
Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and
More informationINSERT COMPANY LOGO HERE
2013 2014 INSERT COMPANY LOGO HERE 2014 North American 2013 North Positron American Emission SSL Tomography Certificate (PET) Imaging Technology Product Innovation Leadership Leadership Award Award Industry
More informationIntegration of PT in an existing radiation oncology center
Integration of PT in an existing radiation oncology center Tom Depuydt, PhD Head of medical Physics, Radiation Oncology UZ Leuven-KU Leuven and ParTICLe proton therapy project tom.depuydt@uzleuven.be 1
More informationModern Hadron Therapy Gantry Developments. 16th Jan 2014
Modern Hadron Therapy Gantry Developments 16th Jan 2014 Protect, Enhance, and Save Lives - 2 - IBA ProteusONE THE TREND: MORE COMPACT, CHEAPER Access to PT is key ProteusPLUS ProteusONE 18000 ft² / 1672
More informationPlans for the Precision Cancer Medicine Institute University of Oxford
Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The
More informationIBA Dosimetry Company Presentation. Patient Safety & Quality Control
IBA Dosimetry Company Presentation Patient Safety & Quality Control IBA Mission Protect, enhance and save lives Protect, Enhance, and Save Lives - 2 - The History of IBA Dosimetry A story of innovation
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationFocusing our energy on saving lives
October 2017 The Outlook for Oncology: The Shrinking, Affordable Proton Therapy Center Focusing our energy on saving lives Jonathan Farr, DSc Senior Vice President Medical Physics Forward Looking Statement
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationRadiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions
Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment
More informationSUMITOMO Particle Therapy Technologies
55 th AAPM annual meeting Particle Beam Therapy Symposium SUMITOMO Particle Therapy Technologies August 3, 2013 Yukio Kumata Experience accelerators for science Current Status proton and carbon Future
More information1ª Jornada de Análisis de Riesgos en RT. 10 de Dic 2014 José Luis Roldán
Risk in Dosimetry. Industry Stand point 1ª Jornada de Análisis de Riesgos en RT. 10 de Dic 2014 José Luis Roldán Agenda IBA. IBA Dosimetry Risks in Dosimetry Product development Product manufacturing Product
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationClinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationUnited States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022
United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 United States Proton Therapy Market (Actual & Potential), Patients Treated,
More informationEfficient Dosimetry for Proton Therapy
Efficient Dosimetry for Proton Therapy Why IBA Dosimetry? IBA Dosimetry offers the full product range tailored to fit any Proton Therapy QA needs. PT treatment safety, as well as most efficient dosimetry
More informationContinuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment
Continuing the momentum to deliver improved performance Robert Cascella Chief Business Leader Diagnosis & Treatment Key takeaways Diagnosis & Treatment strategy is aligned with the Quadruple Aim Gaining
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSCANNER & SERVICES OVERVIEW
SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationiba-worldwide.com REACHING MORE PATIENTS
iba-worldwide.com REACHING MORE PATIENTS IBA s Mission TO DEVELOP CUTTING-EDGE TECHNOLOGY IN THE FIGHT AGAINST CANCER IBA is the world leader in cutting-edge technology as applied to radiotherapy treatment
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationImage Guided Proton Therapy and Treatment Adaptation
Image Guided Proton Therapy and Treatment Adaptation www.hollandptc.nl d.r.schaart@tudelft.nl Cancer in The Netherlands About 1 in 3 people get cancer in some stage of their life 86.800 new cancer patients
More informationDIGITAL DIABETES CARE MARKET READY TO TAKE OFF
DIGITAL DIABETES CARE MARKET 2018-2022 READY TO TAKE OFF www.research2guidance.com A market study about diabetes apps, connected devices, and services 3 rd edition, 3 rd September 2018 Research2Guidance
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationOverview of Advanced Techniques in Radiation Therapy
Overview of Advanced Techniques in Radiation Therapy Jacob (Jake) Van Dyk Manager, Physics & Engineering, LRCP Professor, UWO University of Western Ontario Acknowledgements Glenn Bauman Jerry Battista
More informationElekta - a partner and world-leading supplier
Experience Elekta Elekta - a partner and world-leading supplier of clinical solutions for image guided radiation therapy, stereotactic radiotherapy, radiosurgery and brachytherapy, as well as advanced
More informationVarian and BrainLAB this historically strong relationship has evolved and is set to unlock infinite possibilities Varian Medical Systems, the world s leading manufacturer of radiotherapy and radiosurgery
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationAccuBoost non invasive, real-time, image guided breast boosting
AccuBoost non invasive, real-time, image guided breast boosting A new treatment option for the boost dose as part of the Whole Breast Irradiation treatment after breast cancer AccuBoost is a new system
More informationiviewdose Confidence and assurance in dose delivery
iviewdose Confidence and assurance in dose delivery As radiotherapy techniques advance and treatment plans become more complex, involving escalated doses and increasingly conformal deliveries, the need
More informationEssential Oil & Aromatherapy Market Research Report- Forecast to 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/3319 Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report / Search Code: MRFR/F-B & N/2386-HCRR
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationProtura Robotic Patient Positioning System. for efficiency + performance
Protura Robotic Patient Positioning System for efficiency + performance Protura Robotic Patient Positioning System The Protura Robotic Patient Positioning System is the ultimate in robotic patient motion
More informationHong Kong Sanatorium & Hospital Introduces First-in-Asia TomoHD System
For Immediate Release Hong Kong Sanatorium & Hospital Introduces First-in-Asia TomoHD System (8 March 2011, Hong Kong) Hong Kong Sanatorium & Hospital (HKSH) announces today the introduction of the first-in-asia
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationWorkshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May
IONTRIS Synchrotron based PT Solutions from Siemens AG Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May 1 2009 Matthias Herforth VP Business Development and Communications Siemens AG
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationThe Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons
The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD The Promise of Protons The Promise of Protons Cancer and radiation therapy The promise of protons UFHPTI: missions and operation
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationEconomic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US
Economic Implications of Advancements in Radiation Technology Sponsored by: OTN Anthony M. Berson, M.D. Radiation Oncology, St. Vincent s Comprehensive Cancer Center Richard Emery Vice President, Aptium
More informationPoland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022
Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationExpanding the boundaries of nutrition Luis Cantarell
Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationPROGRESS IN HADRONTHERAPY
PROGRESS IN HADRONTHERAPY Saverio Braccini TERA Foundation for Oncological Hadrontherapy IPRD06 - Siena - 01.10.06 - SB 1 Outline Introduction Radiation therapy with X rays and hadrontherapy Hadrontherapy
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationCepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012
Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationImportant information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar
More informationVarian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy
Varian Acuity BrachyTherapy Suite One Room Integrated Image-Guided Brachytherapy The Acuity BrachyTherapy Suite Integrating Imaging, Planning, and Treatment in a Single Room Each component draws on the
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationNutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to
More information7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift
People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and
More informationTobacco Insights May
Tobacco Insights 2015 - May Product Code: TI0017MR Published Date: June 2015 Report Price: US$ 150 (Single Copy) Synopsis Tobacco Insights 2015 - May report is a qualitative report providing extensive
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationClinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management
Clinical Precision for Best Cancer Care Dee Mathieson Senior Vice President Oncology Business Line Management Optimizing clinical results Key drivers in modern Radiation Therapy Clinical precision Continuous
More information2015 Investor Conference
2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global
More informationTreatment Efficiency and Optimization of Patient Care with IBA ProteusOne
Treatment Efficiency and Optimization of Patient Care with IBA ProteusOne Terry Wu, Ph.D. Chief Physicist, Radiation Oncology Department Willis-Knighton Cancer Center/Proton Therapy Center Shreveport,
More informationThe Global Alliance for Improved Nutrition
The Global Alliance for Improved Nutrition JCIE Seminar on Challenges in Global Health: New Opportunities for the Private Sector 27 July 2010, Tokyo 1 Outline Why Nutrition Matters About GAIN GAIN Nutrition
More informationSolvay expands its specialty polymers offerings with Ryton PPS acquisition
Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationOPPORTUNITIES IN BRACHYTHERAPY
OPPORTUNITIES IN BRACHYTHERAPY EDITION 2014 A report written by Paul-Emmanuel Goethals & Richard Zimmermann www.medraysintell.com Brachytherapy THE FIRST COMPREHENSIVE EVALUATION OF THE BRACHYTHERAPY INDUSTRY
More informationON SHELF AVAILABILITY ALIGNMENT PROJECT 2011 ASIA PAC SURVEY RESULTS
ON SHELF AVAILABILITY ALIGNMENT PROJECT 2011 ASIA PAC SURVEY RESULTS Introduction The ECR Asia Pacific OSA working group conducted an online survey between July and September 2011 aimed at gaining insights
More information